SLC5A2 and heart failure: In the same manner, Empagliflozin recorded a significant decrease in both the EMPEROR-Reduced trials and EMPEROR-Preserved reaffirming the cross-cutting effect of SGLT2 inhibitor in varying heart failure cohorts.